Consequently, in both HLA-DR4-mismatched and -matched settings, memory or CD276-depleted memory CD4+ T-cell grafts significantly improved survival (Fig. 3a) and extended lifespan of the recipients to the end of the predetermined endpoint of the study, compared to bulk CD4+ T-cell recipients (median survival time (MST) = 35 days in case of HLA-DR4negative donors, MST = 60 days in case of HLA-DR4positive donors), and improved clinical GVHD scores (Fig. 3b). The gene discussed is CD276; the disease is graft versus host disease.